Vertex Pharmaceuticals | VRTX - Pre Tax Profit

Stock Price
477.92
Daily Change
19.11 4.17%
Monthly
-1.29%
Yearly
1.83%
Q1 Forecast
455.43

Vertex Pharmaceuticals reported $1.3B in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Incyte USD 482.31M 75.7M Sep/2025
Insmed USD -368.7M 48.26M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
United Therapeutics USD 438M 29.6M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025